Clinicopathological Impact of the Interaction Between Megakaryocytes and Myeloid Stroma in Chronic Myeloproliferative Disorders: A Concise Update

References

• Bentley S. A. Bone marrow connective tissue and the haematopoietic microenvironment. Br. J. Haematol. 1982; 50: 1–6
   PubMed Web of Science ®Google Scholar
• McCarthy D. M. Fibrosis of the bone marrow: Content and causes. Br. J. Haematol. 1985; 59: 1–7
   PubMed Web of Science ®Google Scholar
• Lewis S. M. Myelofibrosis: Historical perspective. Myelofibrosis, Pathophysiology and Clinical Management, S. M. Lewis. Marcel Dekker, New York 1985; 1–13
   Google Scholar
• Charron D., Robert L., Couty M. C., Binet J. L. Biochemical and histological analysis of bone marrow collagen in myelofibrosis. Br. J. Haematol. 1979; 41: 151–61
   PubMed Web of Science ®Google Scholar
• Gay S., Gay R. E., Prchal J. T. Immunohistological studies of bone marrow collagen. Myelofibrosis and the Biology of Connective Tissue, P. Berk, H. Castro-Malaspina, L. Wasserman. Alan R. Liss, New York 1984; 291–306
   Google Scholar
• Apaja-Sarkkinen M., Autio-Harmainen H., Alavaikko M., Risteli J., Risteli L. Immunohistochemical study of basement membrane proteins and type III procollagen in myelofibrosis. Br. J. Haematol. 1986; 63: 571–580
   PubMed Web of Science ®Google Scholar
• Reilly J. T., Nash J. R. G., Mackie M. J., McVerry B. A. Endothelial cell proliferation in myelofibrosis. Br. J. Haematol. 1985; 60: 625–630
   PubMed Web of Science ®Google Scholar
• Lisse I., Hasselbach H., Junker P. Bone marrow stroma in idiopathic myelofibrosis and other haematological diseases. An immunohistological study. APMIS 1991; 99: 171–178
   PubMed Web of Science ®Google Scholar
• Reilly J. T., Nash J. R. G., Mackie M. J., McVerry B. A. Immuno-enzymatic detection of fibronectin in normal and pathological tissue. Br. J. Haematol. 1985; 59: 497–504
   PubMed Web of Science ®Google Scholar
• Roberts A. B., Sporn M. B., Assoian R. K., Smith J. M., Roche N. S., Wakefield L. M., Heine U. I., Liotta L. A., Falanga V., Kehrl J. H., Fauci A. S. Transforming growth factor type β: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl. Acad. Sci. USA 1986; 83: 4167–4171
   PubMed Web of Science ®Google Scholar
• Hasselbach H. On the pathogenesis of angiogenesis in idiopathic myelofibrosis. Am. J. Hematol. 1990; 33: 151
   PubMed Web of Science ®Google Scholar
• Thiele J., Rompcik V., Wagner S. T., Fischer R. Vascular architecture and collagen type IV in primary myelofibrosis and polycythaemia vera: An immunomorphometric study on trephine biopsies of the bone marrow. Br. J. Haematol. 1992; 80: 227–234
   PubMed Web of Science ®Google Scholar
• Burkhardt R., Bartl R., Jaeger K., Frisch B., Kettner G., Mahl G., Sund M. Chronic myeloproliferative disorders (CMPD). Path. Res. Pract. 1984; 179: 131–186
   PubMed Web of Science ®Google Scholar
• Frisch B., Bartl R. Histology of myelofibrosis and osteomyelosclerosis. Myelofibrosis, Pathophysiology and Clinical Management, S. M. Lewis. Marcel Dekker, New York 1985; 51–86
   Google Scholar
• Georgii A., Vykoupil K. F., Buhr T., Choritz H., Dohler U., Kaloutsi V., Werner M. Chronic myeloproliferative disorders in bone marrow biopsies. Path. Res. Pract. 1990; 186: 3–27
   PubMed Web of Science ®Google Scholar
• Buhr T., Georgii A., Choritz H. Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification. Path. Res. Pract. 1993; 189: 121–132
   PubMed Web of Science ®Google Scholar
• Bartl R., Frisch B., Wilmanns W. Potential of bone marrow biopsy in chronic myeloproliferative disorders (MPD). Eur. J. Haematol. 1993; 50: 41–52
   PubMed Web of Science ®Google Scholar
• Dickstein J. I., Vardiman J. W. Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes. Am. J. Clin. Pathol. 1993; 99: 513–525
   PubMed Web of Science ®Google Scholar
• Adamson J. W., Fialkow P. J. The pathogenesis of myeloproliferative disorders. Br. J. Haematol. 1978; 38: 299–303
   PubMed Web of Science ®Google Scholar
• Jacobson R. J., Salo A., Fialkow P. J. Agnogenic myeloid metaplasia: A clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 1978; 51: 189–94
   PubMed Web of Science ®Google Scholar
• Groopman J. E. The pathogenesis of myelofibrosis in myeloproliferative disorders. Ann. Intern. Med. 1980; 92: 857–858
   PubMed Web of Science ®Google Scholar
• Huang S., Terstappen L. W. Formation of hematopoietic microenviroment and haematopietic stem cells from single human bone marrow stem cells. Nature 1992; 360: 745–749
   PubMed Web of Science ®Google Scholar
• Greenberg B. R., Wilson F. D., Woo L., Jenks H. M. Cytogenetics of fibroblastic colonies in PH1-positive chronic myelogenous leukemia. Blood 1978; 51: 1039–1044
   PubMed Web of Science ®Google Scholar
• Golde D. W., Hocking W. G., Quan S. G., Sparkes R. S., Gale R. P. Origin of human bone marrow fibroblasts. Br. J. Haematol. 1980; 44: 183–187
   PubMedGoogle Scholar
• Castro-Malaspina H., Gay R. E., Resnick G., Kapoor N., Meyers P., Chiarieri D., McKenzie S., Broxmeyer H. E., Moore M. A. S. Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood 1980; 56: 289–301
   PubMed Web of Science ®Google Scholar
• Greenberg B. R., Woo L., Veomett I. C., Payne C. M., Ahmann F. R. Cytogenetics of bone marrow fibroblastic cells in idiopathic chronic myelofibrosis. Br. J. Haematol. 1987; 66: 487–490
   PubMed Web of Science ®Google Scholar
• O'Brian S., Kantarjan H., Shtalrid M., Blick M., Beran M., Talpaz M. Lack of cluster region rearrangement in marrow fibroblasts of patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Hematol. Pathol. 1988; 2: 25–29
   PubMedGoogle Scholar
• Wang J. C., Lang H. D., Lichter S., Weinstein M., Benn P. Cytogenetic studies of bone marrow fibroblasts cultured from patients with myelofibrosis and myeloid metaplasia. Br. J. Haematol. 1992; 80: 184–188
   PubMed Web of Science ®Google Scholar
• Waller E. K., Olweus J., Lund-Johansen F., Huang S., Nguyen M., Guo G. R., Terstappen L. The “common stem cell” hypothesis reevaluated: Human fetal bone marrow contains separate populations of hematopoietic and stromal progenitors. Blood 1995; 85: 2422–2435
   PubMed Web of Science ®Google Scholar
• Bhatia R., McGlave P. M., Dewald G. W., Blazar B. R., Verfaillie C. M. Abnormal function of the bone marrow microenviroment in chronic myelogenous leukemia: Role of malignant stromal macrophages. Blood 1995; 85: 3636–3645
   PubMed Web of Science ®Google Scholar
• Castro-Malaspina H. Pathogenesis of myelofibrosis: Role of ineffective megakaryopoiesis and megakaryocyte components. Myelofibrosis and the Biology of Connective Tissue, P. Berk, H. Castro-Malaspina, L. Wasserman. Alan R Liss, New York 1984; 427–454
   Google Scholar
• Reilly J. T. Pathogenesis of idiopathic myelofibrosis: Role of growth factors. J. Clin. Pathol. 1992; 45: 461–464
   PubMed Web of Science ®Google Scholar
• Kimura A., Katoh O., Hyodo H., Kuramoto A., Satow Y. Platelet derived growth factor expression, myelofibrosis and chronic myelogenous leukemia. Leukemia Lymphoma 1995; 18: 237–242
   PubMed Web of Science ®Google Scholar
• Hiti-Harper J., Wohl H., Harper E. Platelet factor 1978; 4, An inhibitor of collagenase. Science; 199:991–992
   Google Scholar
• Chernoff A., Levine R. F., Goodman D. S. Origin of platelet-derived growth factor in megakaryocytes in guinea pigs. J. Clin. Invest. 1979; 65: 926–930
   Web of Science ®Google Scholar
• Scher C. D., Shepard R. C., Antoniades H. N., Stiles C. D. Platelet-derived growth factor and the regulation of the mammalian fibroblast cell cycle. Biochim. Biophys. Acta 1979; 560: 217–241
   PubMed Web of Science ®Google Scholar
• Burstein S. A., Malpass T. W., Yee E., Kadin M., Bridgen M., Adamson J. W., Marker L. A. Platelet factor 4-excretion in myeloproliferative disease: Implications for the aetiology of myelofibrosis. Br. J. Haematol. 1984; 57: 383–392
   PubMed Web of Science ®Google Scholar
• Assoian R. K., Grotendorst G. R., Miller D. M., Sporn M. B. Cellular transformation by coordinated action of three peptide growth factors from human platelets. Nature 1984; 309: 804–806
   PubMed Web of Science ®Google Scholar
• Castro-Malaspina H., Rabellino E., Yen A., Nachman R. L., Moore M. A. S. Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts. Blood 1981; 57: 781–787
   PubMed Web of Science ®Google Scholar
• Bernabei P. A., Arcangeli A., Casini M., Grossi A., Padovani R., Rossi Ferrini P. Platelet-derived growth factor(s) mitogenic activity in patients with myeloproliferative disease. Br. J. Haematol. 1992; 63: 353–357
   Google Scholar
• Kimura A., Katoh O., Kuramoto A. Effects of platelet-derived growth factor, epidermal growth factor and transforming growth factor-β on the growth of human marrow fibroblasts. Br. J. Haematol. 1988; 69: 9–12
   PubMed Web of Science ®Google Scholar
• Katoh O., Kimura A., Kuramoto A. Platelet-derived growth factor is decreased in patients with myeloproliferative disorders. Am. J. Hematol. 1988; 27: 276–280
   PubMed Web of Science ®Google Scholar
• Baglin T. P., Price S. M., Boughton B. J. A reversible defect of platelet PDGF content in myeloproliferative disorders. Br. J. Haematol. 1988; 69: 483–486
   PubMed Web of Science ®Google Scholar
• Kimura A., Katoh O., Hyodo H., Kuramoto A. Transforming growth factor-β regulates growth as well as collagen and fibronectin synthesis of human marrow fibroblasts. Br. J. Haematol. 1989; 72: 486–491
   PubMed Web of Science ®Google Scholar
• Katoh O., Kimura A., Itoh T., Kuramoto A. Platelet derived growth factor messenger RNA is increased in bone marrow megakaryocytes in patients with myeloproliferative disorders. Am. J. Hematol. 1990; 35: 145–150
   PubMed Web of Science ®Google Scholar
• Rueda F., Piñol G., Marti F., Pujol-Moix N. Abnormal levels of platelet-specific proteins and mitogenic activity in myeloproliferative disease. Acta Haematol. 1991; 85: 12–15
   PubMed Web of Science ®Google Scholar
• Martyré M. C. Platelet PDGF and TGF: Levels in myeloproliferative disorders. Leukemia Lymphoma 1991; 6: 1–6
   PubMed Web of Science ®Google Scholar
• Kimura A., Nakata Y., Hyodo H., Kuramoto A., Satow Y. Platelet-derived growth factor expression in accelerated and blastic phase of chronic myelogeneous leukaemia with myelofibrosis. Br. J. Haematol. 1994; 86: 303–307
   PubMed Web of Science ®Google Scholar
• Martyré M. C., Romquin N., Bousse-Kerdiles M. C., Chewillard S., Benyahia B., Dupriez B., Demory J. L., Bauters F. Transforming growth factor-β and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br. J. Haematol. 1994; 88: 9–16
   PubMed Web of Science ®Google Scholar
• Maryré M. C. TGF-β and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders. Leukemia Lymphoma 1995; 20: 39–44
   PubMed Web of Science ®Google Scholar
• Wickenhauser C., Hillienhof A., Jungheim K., Lorenzen J., Ruskowski H., Hansmann M.-L., Thiele J., Fischer R. Detection and quantification of transforming growth factor β (TGF-β) and platelet derived growth factor (PDGF) release by normal human megakaryocytes. Leukemia 1995; 9: 310–315
   PubMed Web of Science ®Google Scholar
• Wickenhauser C., Lorenzen J., Thiele J., Hillienhof A., Jungheim K., Schmitz B., Hansmann M.-L., Fischer R. Secretion of cytokines (interleukins-1α, -3, and -6 and granulocyte-macrophage colony-stimulating factor) by normal human bone marrow megakaryocytes. Blood 1995; 85: 685–691
   PubMed Web of Science ®Google Scholar
• Schmitz B., Thiele J., Kaufmann R., Witte O., Wickenhauser C., Kuhn-Regnier F., Fischer R. Megakaryocytes and fibroblasts-interactions as determined in normal human bone marrow specimens. Leukemia Res. 1995; 19: 629–637
   PubMed Web of Science ®Google Scholar
• Schmitz B., Thiele J., Witte O., Kaufmann R., Wickenhauser C., Fischer R. Influence of cytokines (IL-1α, IL-3, IL-11, GM-CSF) on megakaryocyte-fibroblast interactions in normal human bone marrow. Eur. J. Haematol. 1995; 55: 24–32
   PubMed Web of Science ®Google Scholar
• Kimura A., Katoh O., Hyodo H., Kusumi S., Kuramoto A. Autocrinie and/or paracrine meachnism operate during the growth of human bone marrow fibroblasts. Br. J. Haematol. 1991; 78: 469–473
   PubMed Web of Science ®Google Scholar
• Singal R., Belliveau R. R. Quantification of megakaryocytes in normal bone marrow. Analyt. Quant. Cytol. Histol. 1988; 10: 33–36
   PubMed Web of Science ®Google Scholar
• Lazzarino M., Morra E., Castello A., Inverardi D., Coci A., Pagnuco G., Magrini U., Zei G., Bernasconi C. Myelofibrosis in chronic granulocytic leukemia. Br. J. Haematol. 1986; 64: 227–240
   PubMed Web of Science ®Google Scholar
• Burkhardt R. Bone marrow in megakaryocytic disorders. Hematol. Oncol. Clin. N. Am. 1988; 2: 695–733
   PubMed Web of Science ®Google Scholar
• Kaloutsi V., Fritsch R. S., Buhr T., Restrepo-Specht I., Widjaja W., Georgii A. Megakaryocytes in chronic myeloproliferative disorders: Numerical density correlated between different entities. Virchows Archiv A Pathol. Anat. 1991; 418: 493–497
   Google Scholar
• Thiele J., Hoeppner B., Zankovich R., Fischer R. Histomorphometry of bone marrow biopsies in primary osteomyelofibrosis/-sclerosis (agnogenic myeloid metaplasia)—correlations between clinical and morphological features. Virchows Archiv A Pathol. Anat. 1989; 415: 191–202
   Google Scholar
• Thiele J., Wienhold S., Zankovich R., Fischer R. A histomorphometric analysis of trephine biopsies of bone marrow from 65 patients with chronic myeloid leukemia. Classification of patients into subgroups with different survival patterns. Analyt. Quant. Cytol. Histol. 1990; 12: 103–116
   PubMed Web of Science ®Google Scholar
• Gatter K. C., Cordell J. L., Turley H., Heryet A., Kiefer N., Anstee D. J., Mason D. J. The immunohistological detection of platelet, megakaryocytes and thrombi in routinely processed specimens. Histopathology 1988; 13: 257–267
   PubMed Web of Science ®Google Scholar
• Thiele J., Fischer R. Megakaryocytopoiesis in haematological disorders: Diagnostic features of bone marrow biopsies. Virchows Archiv A Pathol. Anat. 1991; 418: 87–97
   Google Scholar
• Thiele J., Kvasnicka H. M., Titius B. R., Parpert U., Nebel R., Zankovich R., Dienemann D., Stein H., Diehl V., Fischer R. Histological features of prognostic significance in CML-an immunohistochemical and morphometric study (multivariate regression analysis) on trephine biopsies of the bone marrow. Ann. Hematol. 1993; 66: 291–302
   PubMed Web of Science ®Google Scholar
• Thiele J., Kvasnicka H. M., Niederle N., Zirbes T. K., Schmidt M., Dammasch J., Meuter B. R., Leder L.-D., Kloke O., Diehl V., Fischer R. The impact of interferon versus busulfan therapy on the reticulin stain-measured fibrosis in CML-a comparative morphometric study on sequential trephine biopsies. Ann. Hematol. 1995; 70: 121–128
   PubMed Web of Science ®Google Scholar
• Kvasnicka H. M., Thiele J., Amend T., Fischer R. Three-dimensional (3D) reconstruction of histological structures in human bone marrow from serial sections of trephine biopsies: The stereological appearance of sinusoidal vessels in primary (idiopathic) osteomyelofibrosis. Analyt. Quant. Cytol. Histol. 1994; 16: 159–166
   PubMed Web of Science ®Google Scholar
• Thiele J., Titius B. R., Kopsidis C., Fischer R. Atypical micromegakaryocytes, promegakaryoblasts and megakaryoblasts: A critical evaluation by immunohisto-chemistry and morphometry of bone marrow trephines in chronic myeloid leukemia and myelodysplastic syndromes. Virchows Archiv B Cell Pathol. 1992; 62: 275–282
   Google Scholar
• Dekmezian R., Kantarjian H. M., Keating M., Talpaz M., McCredie K. B., Freireich E. J. The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer 1987; 57: 1739–1743
   Web of Science ®Google Scholar
• Lohmann T. B., Beckman E. N. Progressive myelofibrosis in agnogenic myeloid metaplasia. Arch. Pathol. Lab. Med. 1983; 107: 593–594
   PubMed Web of Science ®Google Scholar
• Manoharan A., Pitney W. R. Chemotherapy resolves symptoms and reverses fibrosis in myelofibrosis. Scand. J. Haematol. 1984; 33: 453–459
   PubMedGoogle Scholar
• Charbord P., Neel H., Caillou B., Kahn E., Parmentier C. Effect of alkylating agents on hematopoiesis in myelofibrosis. Nouv. Rev. Fr. d'Hématol. 1984; 26: 361–369
   PubMedGoogle Scholar
• Wolf B. C., Neiman R. S. Myelofibrosis with myeloid metaplasia: Pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly. Blood 1985; 65: 803–809
   PubMed Web of Science ®Google Scholar
• Ellis J. T., Peterson P., Geller S. A., Rappaport H. Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin. Hematol. 1989; 23: 144–155
   Google Scholar
• Thiele J., Simon K. G., Fischer R., Zankovich R. Follow-up studies with sequential bone marrow biopsies in chronic myeloid leukemia and so-called primary (idiopathic) osteo-myelofibrosis. Evolution of histopathological lesions and clinical courses in 40 patients. Pathol. Res. Pract. 1988; 183: 434–445
   PubMed Web of Science ®Google Scholar
• Löfvenberg E., Wahlin A., Roos G., Öst Å. Reversal of myelofibrosis by hydroxyurea. Eur. J. Haematol. 1990; 44: 33–38
   PubMed Web of Science ®Google Scholar
• Hasselbach H., Lisse I. A sequential histological study of bone marrow fibrosis in idiopathic myelofibrosis. Eur. J. Haematol. 1991; 46: 285–289
   PubMed Web of Science ®Google Scholar
• Buhr T., Choritz H., Georgii A. The impact of megakaryocyte proliferation for the evolution of myelofibrosis. Histological follow-up study in 186 patients with chronic myeloid leukemia. Virchows Archiv A Pathol. Anal. 1992; 420: 473–478
   PubMedGoogle Scholar
• Thiele J., Chen Y. S., Kvasnicka H. M., Diehl V., Fischer R. Evolution of fibro-osteosclerotic bone marrow lesions in primary (idiopathic) osteomyelofibrosis—a histomorphometric study on sequential trephine biopsies. Leukemia Lymphoma 1994; 14: 163–169
   PubMed Web of Science ®Google Scholar
• Mc Glave P. B., Brunning R. D., Hurd D. D., Kim T. H. Reversal of severe bone marrow fibrosis and osteosclerosis following allogeneic bone marrow transplantation for chronic granulocyte leukaemia. Br. J. Haematol. 1982; 52: 189–194
   PubMed Web of Science ®Google Scholar
• Oblon D. J., Elvenbein G. J., Braylam R. C., Jones J., Weiner R. S. The reversal of myelofibrosis associated with chronic myelogenous leukemia after allogeneic bone marrow transplantation. Exp. Hematol. 1983; 11: 681–685
   PubMed Web of Science ®Google Scholar
• Dokal I., Jones L., Deenmamode M., Lewis S. M., Goldman J. M. Allogeneic bone marrow transplantation for primary myelofibrosis. Br. J. Haematol. 1989; 71: 158–159
   PubMed Web of Science ®Google Scholar
• Ifrah N., Gardembas-Pain M., Hunault M., Saint-Andre J. P., Foussard C., Boasson M. Allogeneic bone marrow transplantation for primary myelofibrosis. Br. J. Haematol. 1989; 73: 575–576
   PubMed Web of Science ®Google Scholar
• Granstein R. D., Murphy G. F., Margolis R. J., Byrne M. H., Amento E. P. Gamma-interferon inhibits collagen synthesis in vivo in the mouse. J. Clin. Invest. 1987; 79: 1254–1258
   PubMed Web of Science ®Google Scholar
• Parmeggiani L., Ferrant A., Rodhain J., Michaux J. L., Sokal G. Alpha interferon in the treatment of symptomatic myelofibrosis with myeloid metaplasia. Eur. J. Haematol. 1987; 39: 228–232
   PubMed Web of Science ®Google Scholar
• Hasselbalch H. Interferon in myelofibrosis. Lancet 1988; I: 355
   Google Scholar
• Barosi G., Liberato L. N., Costa A., Ascari E. Cytoreductive effect of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia. Blut 1989; 58: 271–274
   PubMedGoogle Scholar
• Barosi G., Liberato L. N., Costa A., Buratti A., Di Dio F., Salvatore S., Ascari E. Induction and maintenance alpha-interferon therapy in myelofibrosis with myeloid metaplasia. Eur. J. Haematol. 1990; 45: 12–14
   Web of Science ®Google Scholar
• McCarthy D., Clark J., Giles F. The treatment of myelofibrosis with α-interferon. Br. J. Haematol. 1991; 78: 590–591
   PubMed Web of Science ®Google Scholar
• Sacchi S. The role of a α-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM) A concise update. Leukemia Lymphoma 1995; 19: 13–20
   PubMed Web of Science ®Google Scholar
• Bauermeister D. E. Quantification of bone marrow reticulin: A normal range. Am. J. Clin. Pathol. 1971; 56: 24–31
   PubMed Web of Science ®Google Scholar
• Beelen D. W., Graeven U., Elmaagacli A. H., Niederle N., Kloke O., Opalka B., Schaefer W. Prolonged administration of interferon-α in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995; 6: 2981–2990
   Google Scholar
• Branehög I., Ridell B., Swolin B., Weinfeld A. Megakaryocyte quantifications in relation to thrombokinetics in primary thrombocythemia and allied diseases. Scand. J. Haematol. 1975; 15: 321–332
   PubMedGoogle Scholar
• Thiele J., Zankovich R., Schneider G., Kremer B., Fischer R., Diehl V. Primary (essential) thrombocythemia versus polycythemia vera rubra. A histomorphometric analysis of bone marrow features in trephine biopsies. Analyt. Quant. Cytol. Histol. 1988; 10: 375–382
   PubMed Web of Science ®Google Scholar
• Nafe R., Kaloutsi V., Fritsch R. S., Georgii A. Quantitative cytomorphology of megakaryocytes in chronic myeloproliferative disorders-Analysis of planimetric and numeric characteristics by means of a knowledge based system. Exp. Pathol. 1990; 40: 213–219
   PubMedGoogle Scholar
• Nafe R., Georgii A., Kaloutsi V., Fritsch R. S., Choritz H. Planimetric analysis of megakaryocytes in the four main groups of chronic myeloproliferative disorders. Virchows Archiv B Cell Pathol. 1991; 61: 111–116
   Google Scholar
• Thiele J., Wagner S., Bertsch H. P., Wienhold S., Fischer R. Pro-megakaryoblasts in bone marrow tissue from patients with primary (idiopathic) osteo-myelofibrosis (agnogenic myeloid metaplasia). Path. Res. Pract. 1990; 186: 586–596
   Web of Science ®Google Scholar
• Thiele J., Wagner S., Degel C., Dienemann D., Wienhold S., Zankovich R., Fischer R., Stein H. Megakaryocyte precursors (pro- and megakaryoblasts) in bone marrow tissue from patients with reactive thrombocytosis, polycythemia vera and primary (essential) thrombocythemia. An immunomorphometric study. Virchows Archiv B Cell Pathol. 1990; 58: 295–302
   Google Scholar
• Thiele J., Wagner S., Weuste R., Dienemann D., Wienhold S., Zankovich R., Fischer R., Stein H. An immunomorphometric study on megakaryocyte precursor cells in bone marrow tissue from patients with chronic myeloid leukemia (CML). Eur. J. Haematol. 1990; 44: 63–70
   PubMed Web of Science ®Google Scholar
• Thiele J., Hoefer M., Kvasnicka H. M., Bertsch H. P., Zankovich R., Fischer R. Erythropoiesis in CML-immunomorphometric quantification, PCNA-reactivity, and influence on survival. Hematol. Pathol. 1993; 7: 239–249
   PubMedGoogle Scholar
• Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A. G., Gralnick H. R., Sultan C. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British cooperative group. Ann. Intern. Med. 1985; 103: 460–462
   PubMed Web of Science ®Google Scholar
• Den Ottolander G. J., Velde J., Brederoo P., Geraedts J. P. M., Slee P. H. T., Willemze R., Zwaan F. E., Haak H. L., Muller H. P., Bieger R. Megakaryoblastic leukaemia (acute myelofibrosis) A report of three cases. Br. J. Haematol. 1979; 42: 9–20
   PubMed Web of Science ®Google Scholar
• Bain B. J., Catovsky D., O'Brien M., Prentice H. G., Lawlor E., Kumaran T. O., McCann S. R., Matutes E., Galton D. A. G. Megakaryoblastic leukemia presenting as acute myelofibrosis—a study of four cases with the platelet-peroxidase reaction. Blood 1981; 58: 206–213
   PubMed Web of Science ®Google Scholar
• Huang M. J., Li C. Y., Nichols W. L., Young J. H., Katzmann J. A. Acute leukemia with megakaryocyte differentiation: A study of 12 cases identified immunocytochemically. Blood 1984; 64: 427–439
   PubMed Web of Science ®Google Scholar
• Hruban R. H., Kuhajda F. P., Mann R. B. Acute myelofibrosis. Am. J. Clin. Pathol. 1987; 88: 578–588
   PubMed Web of Science ®Google Scholar
• Ribeiro R. C., Oliveira M. S. P., Fairclough D., Hurwitz C., Mirro J., Behm F. G., Head D., Silva M. L. M., Raimondi S. C., Crist W. M., Krance R. Acute megakaryoblastic leukemia in children and adolescents: A retrospective analysis of 24 cases. Leukemia Lymphoma 1993; 10: 299–306
   PubMed Web of Science ®Google Scholar
• Terui T., Niitsu Y., Mahara K., Fujisaki Y., Urushizaki Y., Kohgo Y., Watanabe N., Ogura M., Saito H. The production of transforming growth factor-β in acute megakaryoblastic leukemia and its possible implication in myelofibrosis. Blood 1990; 75: 1540–1548
   PubMed Web of Science ®Google Scholar
• Reilly J. T., Barnett D., Dolan G., Forrest P., Eastham J., Smith A. Characterization of an acute micromegakaryocytic leukaemia: Evidence for the pathogenesis of myelofibrosis. Br. J. Haematol. 1993; 83: 58–62
   PubMed Web of Science ®Google Scholar
• Cervantes F., Rozman C. A multivariate analysis of prognostic factors in chronic myeloid leukemia. Blood 1982; 60: 1298–1304
   PubMed Web of Science ®Google Scholar
• Sokal J. E., Cox E. B., Baccarani M., Tura S., Gomez G. A., Robertson J. D., Tso C. Y., Braun T. J., Clarkson B. D., Cervantes F., Rozman C. The Italian Cooperative CML Study Group. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984; 63: 789–799
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Smith T. L., McCredie K. B., Keating M. J., Walters R. S., Talpaz M., Hester J. P., Bligham G., Gehan E., Freireich E. J. Chronic myelogenous leukemia: A multivariate analysis of the associations of patient characteristics and therapy with survival. Blood 1985; 66: 1326–1335
   PubMed Web of Science ®Google Scholar
• Sokal J. E., Baccarani M., Russo D., Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin. Hematol. 1988; 25: 49–61
   PubMed Web of Science ®Google Scholar
• Kantarjian H., Keating M. J., Smith T. L., Talpaz M., McCredie K. B. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am. J. Med. 1990; 88: 1–8
   PubMed Web of Science ®Google Scholar
• The Italian Cooperative Study Group On Chronic Myeloid Leukemia. Confirmation and improvement of Sokal's prognostic classification of Ph+ chronic myeloid leukemia—the value of early evaluation of the course of the disease. Ann. Hematol. 1991; 63: 307–314
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Deisseroth A. S., Kurzrock R., Estrov Z., Talpaz M. Chronic myelogenous leukemia: a concise update. Blood, 82: 691–703
   PubMed Web of Science ®Google Scholar
• Hehlmann R., Heimpel H., Hasford J., Kolb H. J., Pralle H., Hossfeld D. K. Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994; 84: 4064–4077, the German CML Study Group.
   PubMed Web of Science ®Google Scholar
• Morra E., Lazzarino M., Alimena G., Liberati A. M., Grignani F., Mandelli F., Bernasconi C. The role of interferon in the treatment of chronic myelogenous leukemia: Results and prospects. Leukemia Lymphoma 1992; 6: 305–315
   Web of Science ®Google Scholar
• Ozer H., George S. L., Schiffer C. A., Rao K., Rao P. N., Wurster-Hill D. H., Arthur D. D., Powell B., Gottlieb A., Peterson B. A., Rai K., Testa J. R., LeBeau M., Tantravahi R., Bloomfield C. D. Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood 1993; 82: 2975–2984
   PubMed Web of Science ®Google Scholar
• Niederle N., Kloke O., Wandl U. B., Becher R., Moritz T., Opalka B. Long-term treatment of chronic myelogenous leukemia with different interferons: Results from three studies. Leukemia Lymphoma 1993; 9: 111–119
   PubMed Web of Science ®Google Scholar
• The Italian Cooperative Study Group On Chronic Myeloid Leukimia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N. Engl. J. Med. 1994; 330: 820–825
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Smith T. L., O'Brien S., Beran M., Pierce S., Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann. Intern. Med. 1995; 122: 254–261, The Leukemia Service.
   PubMed Web of Science ®Google Scholar
• Allan N. C., Richards S. M., Shepherd P. C. A. on behalf of the UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. UK Medical Researche Council randomised, multicentre trial of interferon-αnl for chronic myeloid leukaemia: improved survival irrespective of cytogenic response. Lancet 1995; 345: 1392–1397
   PubMed Web of Science ®Google Scholar
• Gralnick H. R., Harbor J., Vogel C. Myelofibrosis in chronic granulocytic leukemia. Blood 1971; 37: 152–162
   PubMed Web of Science ®Google Scholar
• Byssens N., Bourgeois N. H. Chronic myelocytic leukemia versus idiopathic myelofibrosis. A diagnostic problem in bone marrow biopsies. Cancer 1977; 40: 1548–1561
   PubMed Web of Science ®Google Scholar
• Clough V., Geary C. G., Hashimi K., Davson G., Knowlson T. Myelofibrosis in chronic granulocytic leukaemia. Br. J. Haematol. 1979; 42: 515–526
   PubMed Web of Science ®Google Scholar
• Thiele J., Kvasnicka H. M., Zankovich R., Fischer R., Diehl V. Parameters of predictive value in CML-the prognostic impact of histopathological variables in a multivariate regression analysis. Leukemia Lymphoma 1991; 4: 63–74
   PubMed Web of Science ®Google Scholar
• Thiele J., Kvasnicka H. M., Niederle N., Koke O., Schmidt M., Lienhard H., Zirbes T., Meuter R. B., Leder L. D., Fischer R. Clinical and histological features retain their prognostic impact under interferon therapy of CML: A pilot study. Am. J. Hematol. 1995; 50: 30–39
   PubMed Web of Science ®Google Scholar
• Lorand-Metze I., Vasallo J., Souza C. A. Histological and cytological heterogeneity of bone marrow in Philadelphia-positive chronic myelogenous leukaemia at diagnosis. Br. J. Haematol. 1987; 67: 45–49
   PubMed Web of Science ®Google Scholar
• Lorand-Metze I. Bone marrow morphology at diagnosis as a prognostic parameter in Philadelphia-positive chronic myelogenous leukaemia (CML). Br. J. Haematol. 1989; 71: 163
   PubMed Web of Science ®Google Scholar
• Charbord P. Increased vascularity of bone marrow in myelofibrosis. Br. J. Haematol. 1989; 62: 595–596
   Web of Science ®Google Scholar
• Van Dyke D., Anger H. O., Parker H., McRae J., Dobson E. L., Yano Y., Naets J. P., Linfoot J. Markedly increased bone blood flow in myelofibrosis. J. Nucl. Med. 1971; 72: 506–512
   Google Scholar
• Miyazono K., Okabe T., Urabe A., Takaku F., Heldin C. H. Purification and properties of an endothelial cell growth factor from human platelets. J. Biol. Chem. 1987; 262: 4098–4103
   PubMed Web of Science ®Google Scholar
• Folkman J., Klagsbrun M. Angiogenic factors. Science 1987; 235: 442–447
   PubMed Web of Science ®Google Scholar
• Roberts A. B., Heine U. I., Flanders K. C., Spron M. B. Transforming growth factor-β: Major role in regulation of extracellular matrix. Ann. NY. Acad. Sci. 1990; 580: 225–232
   PubMed Web of Science ®Google Scholar
• Vaughan J. M., Harrison C. V. Leuco-erythroblastic anaemia and myelosclerosis. J. Pathol. Bacteriol 1939; 48: 339–352
   Google Scholar
• Partanen S., Ruutu T., Vuopio P. Circulating haematopoietic progenitors in myelofibrosis. Scand. J. Haematol. 1982; 29: 325–330
   PubMedGoogle Scholar
• Hibbin J. A., Njoku O. S., Matutes E., Lewis S. M., Goldman J. M. Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders. Br. J. Haematol. 1984; 57: 495–503
   PubMed Web of Science ®Google Scholar
• Grossi A., Vannuchi A. M., Rafanelli D., Vannucchi L., Ferrini P. R. Megakaryocyte progenitors in the bone marrow and peripheral blood of patients with myeloproliferative diseases. Am. J. Hematol. 1987; 25: 371–376
   PubMed Web of Science ®Google Scholar
• Han Z. C., Briere J., Nedellec G., Abgrall J. F., Sensebe L., Parent D., Guern G. Characteristics of circulating megakaryocyte progenitors (CFU-MK) in patients with primary myelofibrosis. Eur. J. Haemtol. 1988; 40: 130–135
   PubMed Web of Science ®Google Scholar
• Wolf B. C., Neiman R. S. Hypothesis: Splenic filtration and the pathogenesis of extramedullary hematopoiesis in agnogenic myeloid metaplasia. Hematol. Pathol. 1987; 1: 77–80
   PubMedGoogle Scholar
• Falk S., Mix D., Stutte H. J. The spleen in osteomyelofibrosis. A morphological and immunohisto-chemical study of 30 cases. Virchows Archiv A Pathol Anat. 1990; 416: 437–442
   Google Scholar
• O'Keane J. C., Wolf B. C., Neiman R. S. The pathogenesis of splenic extramedullary hematopoiesis in metastatic carcinoma. Cancer 1989; 63: 1539–1543
   PubMed Web of Science ®Google Scholar
• Thiele J., Klein H., Falk S., Bertsch H. P., Fischer R., Stutte H. J. Splenic megakaryocytopoiesis in primary (idiopathic) osteomyelofibrosis. Acta Haematol. 1992; 87: 176–180
   PubMed Web of Science ®Google Scholar
• Lichtman M. A., Chamberlain J. K., Simon W., Santillo P. A. Parasinuoidal location of megakaryocytes in marrow: A determinant of platelet release. Am. J. Hematol. 1978; 4: 303–312
   PubMed Web of Science ®Google Scholar
• Young K. M. Localization of megakaryocytes in bone marrow. Blood cells 1989; 15: 15–21
   PubMedGoogle Scholar
• Thiele J., Kvasnicka H. M., Amend T., Fischer R. Megakaryocytes and sinus walls in primary osteomyelofibrosis: Transendothelial migration as revealed by three-dimensional reconstruction of serial sections following sequential double-immunostaining. Virchows Archiv 1994; 424: 383–387
   PubMed Web of Science ®Google Scholar
• Becker R. P., DeBruyn P. P. H. The transmural passage of blood cells into myeloid sinusoids and the entry of platelets into the sinusoidal circulation; a scanning electron microscopic investigation. Am. J. Anat. 1976; 145: 183–206
   PubMedGoogle Scholar
• Tavassoli M., Aoki M. Migration of entire megakaryocytes through the marrow blood barrier. Br. J. Haematol. 1981; 48: 25–29
   PubMed Web of Science ®Google Scholar
• Melamed M. R., Clifton E. E., Mercer C., Koss L. G. The megakaryocyte blood count. Am. J. Med. Sci. 1966; 252: 301–309
   PubMed Web of Science ®Google Scholar
• Maniatis A. K. Megakaryocytes and platelets in central venous and arterial blood. Am. J. Haemtol. 1969; 42: 330–335
   Web of Science ®Google Scholar
• Hansen M., Pedersen N. T. Circulating megakaryocytes in blood from the antecubital vein in healthy adult humans. Scand. J. Haematol. 1978; 20: 371–376
   PubMedGoogle Scholar
• Pedersen N. T. Occurrence of megakaryocytes in various vessels and their retention in the pulmonary capillaries in man. Scand. J. Haematol. 1978; 221: 369–375
   Google Scholar